Publication & Citation Trends
Publications
0 total
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.
Cited by 0
Semantic Scholar
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Cited by 37
Semantic Scholar
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC.
Cited by 28
Semantic Scholar
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5
Cited by 3
Semantic Scholar
Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
Cited by 19
Semantic Scholar
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-PD-(L)1 Plus Platinum Chemotherapy.
Cited by 16
Semantic Scholar
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1.
Cited by 5
Semantic Scholar
1463 Coformulated vibostolimab/pembrolizumab plus chemotherapy as first-line therapy vs atezolizumab plus chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): randomized, phase 3 KEYVIBE-008 OA
Cited by 3
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(636)
Lung Cancer Research Studies
(486)
Cancer Immunotherapy and Biomarkers
(296)
Peptidase Inhibition and Analysis
(217)
Lung Cancer Diagnosis and Treatment
(207)
Affiliations
Universidad Complutense de Madrid
Hebron University
Universitat Autònoma de Barcelona
Hershey (United States)
Novartis (Switzerland)